Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Melissa A. Mietzel"'
Autor:
Alex K, Bryant, Huiying, Yin, Matthew J, Schipper, Peter A, Paximadis, Thomas P, Boike, Derek P, Bergsma, Benjamin, Movsas, Robert T, Dess, Melissa A, Mietzel, Randi, Kendrick, Merita, Seferi, Michael M, Dominello, Martha M, Matuszak, Reshma, Jagsi, James A, Hayman, Lori J, Pierce, Shruti, Jolly
Publikováno v:
American journal of clinical oncology. 45(4)
The addition of adjuvant durvalumab improves overall survival in locally advanced nonsmall-cell lung cancer (NSCLC) patients treated with definitive chemoradiation, but the real-world uptake of adjuvant durvalumab is unknown.We identified patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ec9d9e10362e2fb966eea41b3534fbc
https://pubmed.ncbi.nlm.nih.gov/35271524
https://pubmed.ncbi.nlm.nih.gov/35271524
Autor:
James A. Hayman, Michael M. Dominello, Eleanor M. Walker, Frank A. Vicini, Melissa A. Mietzel, Cynthia Holland Browne, Eyad Abu-Isa, Kent A. Griffith, A.M. Laucis, Paul G. Kocheril, Joshua T. Dilworth, Jean M. Moran, Lori J. Pierce, Reshma Jagsi
Publikováno v:
International journal of radiation oncology, biology, physics. 107(5)
Hypofractionated radiation therapy is a less burdensome and less costly approach that is efficacious for most patients with early-stage breast cancer. Concerns about racial disparities in adoption of medical advances motivate investigation of the use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9d1e456483462ce1cc9caaf160a2abe
https://pubmed.ncbi.nlm.nih.gov/32376311
https://pubmed.ncbi.nlm.nih.gov/32376311
Autor:
James A. Hayman, Kent A. Griffith, Martha M. Matuszak, P.A. Paximadis, Melissa A. Mietzel, M.J. Schipper, Reshma Jagsi, Lori J. Pierce, Frank A. Vicini, Brandon R. Mancini, Jean M. Moran, S. Jolly
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:S73
PURPOSE/OBJECTIVE(S) Regional collaborative quality initiatives that incent participation through direct payment and streamlined reimbursement for high-performing sites have been shown to drive improvements in surgical outcomes. Numerous quality meas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ad51c671c1b80909162ec71a31bbe09
https://doi.org/10.1016/j.ijrobp.2021.07.179
https://doi.org/10.1016/j.ijrobp.2021.07.179
Autor:
Michael M. Dominello, Reshma Jagsi, Merita Seferi, Melissa A. Mietzel, Randi Kendrick, Lori J. Pierce, T.P. Boike, Munther Ajlouni, James A. Hayman, Robert T. Dess, Derek P. Bergsma, Peter Paximadis, Huiying Yin, Alex K. Bryant, Benjamin Movsas, Martha M. Matuszak, Shruti Jolly, Matthew J. Schipper
Publikováno v:
Journal of Clinical Oncology. 39:8523-8523
8523 Background: In the landmark PACIFIC trial, adjuvant durvalumab after definitive chemoradiation for unresectable stage III non-small-cell lung cancer (NSCLC) produced a 11% absolute overall survival benefit at two years compared to placebo, and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58d8d626a68ee50eeb2f9af4dbeef268
https://doi.org/10.1200/jco.2021.39.15_suppl.8523
https://doi.org/10.1200/jco.2021.39.15_suppl.8523
Autor:
D.E. Spratt, T.P. Boike, Reshma Jagsi, Melissa A. Mietzel, James A. Hayman, Michael M. Dominello, Martha M. Matuszak, D P Bergsma, P.A. Paximadis, M.J. Schipper, Kimberly A. Hochstedler, A.M. Laucis, Lori J. Pierce, S. Jolly, Robert T. Dess
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:e148
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4cc7989b929632e0710b99587c3a78c0
https://doi.org/10.1016/j.ijrobp.2020.07.1317
https://doi.org/10.1016/j.ijrobp.2020.07.1317
Autor:
Joshua T. Dilworth, Cynthia Holland Browne, Eyad Abu-Isa, Melissa A. Mietzel, Kent A. Griffith, Michael M. Dominello, Reshma Jagsi, Eleanor M. Walker, Lori J. Pierce, Frank A. Vicini, A.M. Laucis, Paul George Kocheril, James A. Hayman, Jean M. Moran
Publikováno v:
Journal of Clinical Oncology. 37:141-141
141 Background: Concerns about racial disparities in the adoption of medical advances motivate investigation of the use of hypofractionated radiotherapy, a less burdensome and less costly approach that is efficacious for most patients with early-stag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f08987b3114702f5fa555302029ee6f7
https://doi.org/10.1200/jco.2019.37.27_suppl.141
https://doi.org/10.1200/jco.2019.37.27_suppl.141
Autor:
James A. Hayman, S. Jolly, Jay Burmeister, Michael M. Dominello, Jan Parker, C. Fraser, Jean M. Moran, D Kendrick, Kent A. Griffith, Melissa A. Mietzel, T.P. Boike, Lori J. Pierce, Brandon R. Mancini, Meredith Wilson, D.E. Spratt, K Baldwin, Lance D. Miller, M Grubb, Stephen J Gardner, L. Jaworski
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 105:S153
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1795238182de3014390918d8b54d67ce
https://doi.org/10.1016/j.ijrobp.2019.06.162
https://doi.org/10.1016/j.ijrobp.2019.06.162
Autor:
Kristen Detweiler-Short, Melissa A. Mietzel, Asra Ahmed, Daniel Lebovic, David H. Vesole, Ravi Vij, Dominik Dytfeld, Terri L. Jobkar, Keith Stockerl-Goldstein, Sundar Jagannath, Kathryn McDonnell, Andrzej Jakubowiak, Mark S. Kaminski, Ammar Al-Zoubi, Daniel R. Couriel, Tara B. Anderson, Jagoda Jasielec, Diane E. Durecki, Kent A. Griffith
Publikováno v:
Haematologica. 99(9)
A number of combination regimens with immunomodulatory agents or proteasome inhibitors have been developed for use in elderly patients with newly diagnosed multiple myeloma (NDMM). Regimens including bortezomib, melphalan, and prednisone (VMP), and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::996f7a43042f9f0b2f42e73598f28f9a
https://pubmed.ncbi.nlm.nih.gov/24972772
https://pubmed.ncbi.nlm.nih.gov/24972772
Autor:
Ravi Vij, Tara B. Anderson, Brian K. Nordgren, Daniel R. Couriel, Kristen Detweiler-Short, Melissa A. Mietzel, Keith Stockerl-Goldstein, Terri L. Jobkar, Andrzej Jakubowiak, Sundar Jagannath, Diane E. Durecki, Mark S. Kaminski, Ammar Al-Zoubi, Daniel Lebovic, Kathryn McDonnell, Kent A. Griffith, Dominik Dytfeld, Asra Ahmed, David H. Vesole
This phase 1/2 study in patients with newly diagnosed multiple myeloma (N = 53) assessed CRd—carfilzomib (20, 27, or 36 mg/m2, days 1, 2, 8, 9, 15, 16 and 1, 2, 15, 16 after cycle 8), lenalidomide (25 mg/d, days 1-21), and weekly dexamethasone (40/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3495fce8557d4e273bfabc7796acffa3
https://europepmc.org/articles/PMC5162553/
https://europepmc.org/articles/PMC5162553/
Autor:
Jennifer Barrickman, Tara B. Anderson, Colleen K. Harvey, Erica L. Campagnaro, Andrzej Jakubowiak, Donna E. Reece, Mark S. Kaminski, Craig L. Tendler, Melissa A. Mietzel, Dixie Lee Esseltine, Robert L. Schlossman, Noopur Raje, S. Lonial, Todd M. Zimmerman, Sandra Wear, Kenneth C. Anderson, Kent A. Griffith, Jacob P. Laubach, Craig C. Hofmeister, Paul G. Richardson, Susan L. Kelley
Publikováno v:
Blood. 118(3)
This phase 1/2 trial evaluated combination lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone (RVDD) in newly diagnosed multiple myeloma (MM) patients. Patients received RVDD at 4 dose levels, including the maximum tolerated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51d50aac9032358498eaf99ad2f61bac
https://pubmed.ncbi.nlm.nih.gov/21596852
https://pubmed.ncbi.nlm.nih.gov/21596852